eli lilly cash pay tirzepatide offers weight-loss drugs in vials at a discount to fight competition Eli Lilly Introduces New Zepbound

WO 00/53148 (Merck) discloses and claims a "method for the treatment of erectile dysfunction which comprises administering to a human subject in need of such treatment an effective amount of an agonist of the melanocortin receptor in combination with an effective amount of a cyclic-GMP- specific phosphodiesterase inhibitor or an alpha-andrenergic receptor antagonist." MT-II is a disclosed melanocortin receptor agonist and sildenafil is a disclosed PDE-5 inhibitor

novel approaches are desirable

CJC-1295 (Mod GRF 1-29): A synthetic analog of GHRH (1-29), designed for improved pharmacokinetics

10.1210/jcem.84.9.6010 J Clin Endocrinol Metab